Karyopharm Therapeutics (NasdaqGS:KPTI) Conference Transcript

Karyopharm Therapeutics Conference Summary Company Overview - Karyopharm Therapeutics is a U.S.-based, innovation-focused, commercial-stage oncology company specializing in areas of high unmet need, particularly in multiple myeloma and myelofibrosis [5][6] - The lead compound, Selinexor (XPOVIO), is already commercialized for multiple myeloma and approved in over 50 countries [5] Key Developments - Karyopharm is excited about two upcoming Phase III trials: one for myelofibrosis and another for endometrial cancer, with results for the myelofibrosis trial (SENTRY) expected in March 2026 [5][6] - The SENTRY trial aims to establish a new standard of care using Selinexor in combination with Ruxolitinib [6] Scientific Rationale - Selinexor is an XPO1 inhibitor that modulates various pathways relevant to myelofibrosis, including the NF-kappa B pathway and tumor suppressors like P53 [9][10] - The Phase I study showed that 79% of patients achieved a spleen volume reduction of 35% (SVR35) at week 24 when treated with Selinexor and Ruxolitinib, compared to 30%-35% with Ruxolitinib alone [12] Safety Profile - The safety profile of Selinexor in combination with Ruxolitinib appears manageable, with lower rates of nausea and vomiting compared to previous studies [18][20] - Only 7% of patients discontinued treatment due to adverse events in the Phase III study, indicating a favorable safety profile [18] Clinical Insights - Dr. Claire Harrison, a leading expert in myelofibrosis, emphasized the need for treatments that provide deeper and more durable responses than current JAK inhibitors [26] - The combination of Selinexor and Ruxolitinib is expected to be well-tolerated, with manageable side effects, particularly nausea [32][66] Trial Design and Endpoints - The SENTRY trial involves a two-to-one randomization of 353 patients to receive either Selinexor plus Ruxolitinib or Ruxolitinib plus placebo [40] - Primary endpoints include SVR35 and absolute total symptom score (TSS), with a focus on achieving a statistically significant improvement over Ruxolitinib alone [41][46] Baseline Characteristics - The baseline TSS in the SENTRY trial is higher than in previous trials, which may enhance the likelihood of demonstrating a meaningful treatment effect [52][54] - Dr. Harrison noted that a higher baseline TSS could lead to more accurate assessments of treatment efficacy [54] Future Expectations - A successful outcome in the SENTRY trial would likely lead to the combination being used as a first-line treatment for myelofibrosis patients [63] - The community of physicians is eager for new treatment options, and there is a strong interest in the results of the SENTRY trial [69] Additional Considerations - The trial's design excludes fatigue from the primary endpoints, which has been a challenge in previous studies [44] - The combination therapy is expected to improve hemoglobin levels, which is a critical prognostic factor in myelofibrosis [60] This summary encapsulates the key points discussed during the Karyopharm Therapeutics conference, highlighting the company's focus on innovative treatments for myelofibrosis and the anticipated impact of the SENTRY trial results.